Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.

@article{Laguno2009RandomizedTC,
  title={Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.},
  author={Montserrat Laguno and Carmen Cifuentes and Javier Murillas and Sergio Veloso and Mar{\'i}a Larrousse and Antoni Mairata I Payeras and Lucia Bonet and Francese Vidal and Ana Milinkovi{\'c} and A. Bassa and Concha Villalonga and I. Mara{\~n}a P{\'e}rez and Cristina Tural and Mar{\'i}a Mart{\'i}nez-Rebollar and Marta Calvo and Jos{\'e} L Blanco and Estaban Mart{\'i}nez and J M S{\'a}nchez-Tapias and Jose M. Gatell and Jos{\'e} Mallolas},
  journal={Hepatology},
  year={2009},
  volume={49 1},
  pages={22-31}
}
UNLABELLED Although two pegylated interferons (Peg-IFN) are available to treat chronic hepatitis C virus (HCV) infection, no head-to-head comparative studies have been published. We aim to compare the efficacy and safety of PEG IFN alfa-2b (PEG 2b) versus PEG IFN alfa-2a (PEG 2a), plus ribavirin (RBV). A prospective, randomized, multi-center, open-label clinical trial including 182 human immunodeficiency virus (HIV)-hepatitis C virus (HCV) patients naïve for HCV therapy was performed. Patients… CONTINUE READING